

**NOVEL THERAPEUTIC TARGET FOR TREATING VASCULAR
DISEASES, DYSLIPIDEMIAS AND RELATED DISORDERS**

5

This application claims priority of U.S. Provisional Application Serial
10 No. 60/391,878, filed 27 June 2002, the disclosure of which is hereby
incorporated by reference in its entirety.

15

FIELD OF THE INVENTION

The present invention relates to the discovery of gene95, a novel
therapeutic target for disease diagnosis and treatment, especially diagnosis
and treatment of cardiovascular diseases, such as dyslipidemia and low HDL
20 diseases, including hypoalphalipoproteinemia, as well as therapeutic agents
and methods of screening and identifying therapeutic agents useful in
preventing, treating or otherwise ameliorating such disorders.

25

BACKGROUND OF THE INVENTION

Epidemiological studies have consistently demonstrated that plasma
high density lipoprotein cholesterol (HDL-C) concentration is inversely related
to the incidence of vascular disease, particularly cardiovascular disease

(CVD) and coronary artery disease (CAD). HDL-C levels are a strongly graded and independent cardiovascular risk factor. Protective effects of an elevated HDL-C persist until 80 years of age. A low HDL-C is associated with an increased CAD risk even with normal (<5.2 mmol/l) total plasma cholesterol levels. Even in the face of other dyslipidemias or secondary factors, HDL-C levels are important predictors of CAD. Low HDL cholesterol (in severe cases called hypoalphalipoproteinemia), is also implicated in cerebrovascular disease, coronary restenosis, and peripheral vascular disease.

10

Pharmacological intervention of low HDL-C levels has so far proven unsatisfactory. Currently, there are no FDA approved therapeutic agents which modulate HDL levels in a direct, significant fashion. Current research strategies aimed towards modulating HDL involve increasing production of ApoA1, promoting the rate of reverse cholesterol transport (RCT) and decreasing catabolism of HDL. For example, increasing ApoA1 levels may be possible via small molecular upregulation of transcription or by infusion of ApoA1 protein. Alternatively, it may be possible to upregulate RCT by developing ABCA1 agonists and increasing cholesterol efflux from peripheral tissues (see PCT publication WO 00/55318, incorporated herein by reference). Catabolism of HDL is regulated by a number of enzymes, including Cholesteryl Ester Transfer Protein (CETP), which may also be a suitable therapeutic target for HDL regulation.

Identification of additional genes and corresponding proteins which act to modulate HDL levels in humans would allow rational choice of which therapeutic approach to pursue in terms of drug development. The present invention relates to the discovery of a new target for therapeutic intervention in the treatment of vascular diseases and dyslipidemias and use of said target to screen for and identify therapeutic agents useful in alleviating low HDL levels and the symptoms of attendant disorders.

BRIEF SUMMARY OF THE INVENTION

The present invention provides the complete *gene95* cDNA nucleotide sequence (SEQ ID NO: 3) and *gene95* amino acid sequence (SEQ ID NO: 4) from humans. The invention further identifies the role and function of *gene95* as a key regulator of HDL cholesterol levels by identification of mutant forms of the gene which are associated with inherited low HDL disorders in humans.

In one aspect, the present invention provides the purified nucleic acid sequence of *gene95* and fragments thereof, including purified and semi-purified forms thereof, as well as recombinant cell lines, viruses or cell extracts containing *gene95* nucleotide constructs.

In another aspect, the present invention provides the purified *gene95* protein and fragments thereof, including purified and semi-purified forms thereof, as well as cells or cell extracts containing *gene95* biological activity, and anti-*gene95* antibodies, including methods of making such polypeptides.

In one aspect, the present invention provides a method for determining whether a candidate compound modulates HDL levels and/or treating a vascular disease or dyslipidemia. The method comprises (a) determining a biological activity of the *gene95* gene or protein; (b) contacting a source of this biological activity with a candidate compound under conditions promoting this biological activity; and (c) determining a change in the biological activity of said gene or protein as a result of said contacting, wherein the change in biological activity identifies the candidate compound, or its an analog of the candidate compound, as a compound that modulates said biological activity and is useful in regulating HDL levels and/or treating a vascular disease, dyslipidemia or a related disorder. Other types of assays for *Gene95* activity are also specifically contemplated by the present invention.

In another aspect, the invention provides a method for computationally identifying a compound for modulating HDL levels and/or treating a vascular disease or dyslipidemia. The method involves (a) determining the active site of the gene95 protein selected (for example, through X-Ray crystallography or other techniques); and (b) through computational modeling, identifying a compound which interacts with the active site, thereby identifying a compound, or an analog thereof, as a compound which is useful for modulating HDL levels and/or treating a vascular disease, dyslipidemia or a related disorder.

10

In another aspect, the invention provides a method for modulating HDL levels and/or treating a vascular disease, dyslipidemia or a related disorder, comprising administering to a person in need thereof, a compound which modulates the activity of gene 95 gene or protein.

15

In a further aspect, the invention provides tools for diagnosis of vascular disease and dyslipidemias and/or pharmacogenomics of therapeutic agents for treating vascular disease and dyslipidemias, comprising identification of mutations in the gene95 gene or protein, for example the mutations identified in SEQ ID Nos. 6 – 9 or in Table 1.

20

BRIEF DESCRIPTION OF THE DRAWINGS

25

Figure 1 shows the pedigree of family BC-11M.

Figure 2 shows the pedigree of family NL-003.

30

Figure 3 shows the pedigree of family NL-120.

Figure 4 illustrates the expected 10 exon construct of gene95 cDNA. Incomplete constructs assembled from known fragments of gene95 are also illustrated, including other possible transcripts employing E6a or E9a.

5 Figures 5A-5G provide the sequence of exons and introns and the amino acid translation of gene95. Legend: Lower case letters = intron regions not forming part of mature mRNA or cDNA. "..." = intron regions available from public database; not included herein. Capital Letters = Nucleotide base or Amino Acid (as indicated by context; with standard designations used). "*" = a stop codon. +1, +2, +3: Frameshift for translation of nucleic acid. Short open reading frames before and after the correct amino acid sequence are indicated for completeness, but are not expected to form part of the gene95 protein. Here, exon E1 is part of SEQ ID NO: 18, exon E2 is part of SEQ ID NO: 19, exon E3 is part of SEQ ID NO: 20, exon E4 is part of SEQ ID NO: 21, 10 exon E5 is part of SEQ ID NO: 22, exon E6 is part of SEQ ID NO: 23, exon E7 is part of SEQ ID NO: 24, exon E8 is part of SEQ ID NO: 25, exon E9 is part of SEQ ID NO: 26, exon E10 is part of SEQ ID NO: 27, exon E6a is part of SEQ ID NO: 28, and exon E9a is part of SEQ ID NO: 29. Here, exon 6a = Alternative Exon 6 ("Exon 6 alt") (truncates protein) while exon 9a = 15 Alternative exon 9 ("Exon 9 alt") (longer, but truncates). In addition, ctttga (SEQ ID NO: 30) shows the start of a new intronic sequence.

Figure 6 illustrates the alignment of human (SEQ ID NO: 4) and mouse (SEQ ID NO: 5) amino acid sequences of gene95.

25

Figure 7 shows the alignments of the amino acid sequence of mutation 1 (SEQ ID NO: 7) and mutation 2 (SEQ ID NO: 16) with the wild-type amino acid sequence (SEQ ID NO: 4) of human gene95.

30 Figure 8 illustrates the predicted exon assembly of gene95, with locations of mutations and polymorphisms identified according to the invention.

Figure 9 shows a Northern blot with a Gene 95 probe illustrating the results of Example 3.

5

DEFINITIONS

10 As used herein, the following terms have their indicated meanings unless expressly stated otherwise.

As used herein, the term "correspond" in the sense of "a gene corresponding to gene95", means that the gene has the indicated nucleotide
15 sequence or that it encodes substantially the same RNA as would be encoded by the indicated sequence, the term "substantially" meaning at least about 50% identical over a sequence encoding a protein with gene95 biological activity; more preferably at least about 60%, 70%, 80%, 90% or higher, and as defined elsewhere herein, including splice variants thereof.

20

"Corresponding to gene95" also includes homologs or orthologs of gene95 from another organism, and sequence variants thereof having at least about 50% identity, at either the nucleotide or amino acid level, and more preferably at least about 60%, 70%, 80%, 90% or higher homology.
25 Preferably such gene is from a eukaryote, more preferably a mammal, more preferably a rodent or human. The human genes and proteins listed in this specification are representative of a wide variety of homologs, orthologs and analogs that may be obtained from other species. These homologs, orthologs and/or analogs, and reasonable variants thereof, can be used in the
30 compositions and methods of this invention. For example, a screening assay which uses the mouse homolog of a listed human gene may also be used in a screening assay to identify potential therapeutic agents for treating humans.

As such, the present invention relates to the use of these isoforms, homologs from other species, and analogous sequences which, when translated, retain the biological activity of the isoform, as determined on a region by region basis. Such analogous sequences share preferably greater than 50% identity with SEQ ID NO: 3 or SEQ ID NO: 4, more preferably 60%, 70%, 80% and most preferably at least about 90% identity with the isoforms set out herein. All such sequences may still be useful in practicing the methods of the invention provided that they retain sufficient therapeutic target biological activity so as to determine the effects of test compounds in regulating such activity. Such understanding is available to those skilled in the art based on the teachings disclosed herein.

Further in accordance with the present invention, the term "percent identity" or "percent identical," when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:

$$\text{Percent Identity} = 100 [1 - (C/R)]$$

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence wherein (i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and (ii) each gap in the Reference Sequence and (iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference; and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

If an alignment exists between the Compared Sequence and the Reference Sequence for which the percent identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum percent identity to the Reference Sequence even though alignments may exist in which the hereinabove calculated Percent Identity is less than the specified Percent Identity.

As used herein, the terms "portion," "segment," and "fragment," when used in relation to polypeptides, refer to a continuous sequence of nucleotide residues, sequence forms a subset of a larger sequence. Such terms include the products produced by treatment of said polynucleotides with any of the common endonucleases, or any stretch of polynucleotides that could be synthetically synthesized. These may include exonic and intronic sequences of the corresponding genes.

"Therapeutic target biological activity" (or just "biological activity") as used herein is a very broad term that relates to all the directly or indirectly measurable and identifiable biological activities of the therapeutic target gene and protein, including but not limited to those examples set out in (a) – (d) below:

(a) Relating to the purified therapeutic target protein, therapeutic target biological activity includes, but is not limited to, all those biological processes, interactions, or binding of ligands, proteins, membrane components or other compounds (such as small organic compounds), binding behavior, binding-activity relationships, pKa, pD, enzyme kinetics, stability, and functional assessments of the protein.

(b) Relating to therapeutic target biological activity in cell fractions, reconstituted cell fractions or whole cells, these activities include, but are not limited to the ligand or antibody binding behavior and all measurable

consequences of this effect, such as measurement of any signaling cascade, efflux, influx or accumulation, stability or degradation of cellular components, membrane composition and behavior, cell growth, development or behavior and other direct or indirect effects of therapeutic target activity.

5

(c) Relating to therapeutic target genes and transcription, therapeutic target biological activity includes the rate, scale or scope of transcription of DNA to generate therapeutic target mRNA or its alternate transcripts; the effect of regulatory proteins on such transcription, the effect of modulators of such regulatory proteins on such transcription; plus the stability and behavior of mRNA transcripts, post-transcription processing, mRNA amounts and turnover, and all measurements of translation of the mRNA into polypeptide sequences.

15 (d) Relating to therapeutic target biological activity in organisms, this includes but is not limited to biological activities which are identified by their absence or deficiency in disease processes or disorders caused by aberrant therapeutic target biological activity in those organisms. Broadly speaking, therapeutic target biological activity can be determined by all these and other means for analyzing biological properties of proteins and genes that are known in the art.

25

DETAILED DESCRIPTION OF THE INVENTION

In accordance with the present invention, a gene and protein associated with maintenance of HDL levels in humans has been determined by identification of mutant forms of the gene in families having low HDL levels using the positional cloning strategy set out in Example 1.

30

The pedigree of family BC-11M is shown in Figure 1. The phenotype in the family used to define the linkage segregates a low HDL (hypoalphalipoproteinemia) trait in an autosomal dominant fashion with high penetrance. Other lipid parameters are normal in this family (including triglyceride (TG) and low density lipoprotein (LDL)) and there is an absence of other confounders (such as obesity and diabetes). There is strong evidence for cardiovascular disease and coronary artery disease in particular in this family as multiple members have had cardiac events (myocardial infarct (MI), stroke and angina) and have been treated for symptoms of this disease (such as with coronary artery bypass graft (CABG)). One member of this family has Behcet syndrome (related to lupus and auto-immune disorders; another member has celiac disease (gluten intolerance) and others have thyroid problems.

Members of this family had the wild type sequence for coding regions of ABCA1, thus distinguishing them from the previously identified low-HDL causing mutations in ABCA1. In addition, the ABCA1 gene is excluded based on the genetics of this family, and based on normal cholesterol efflux measurements in cultured fibroblasts from affected individuals in this family.

The pedigree of family NL-003 is shown in Figure 2. The proband (II:35) has an HDL level below the fifth percentile (age and sex corrected). There are a few cases of overweight/obesity ($BMI > 25 > 30$) but this condition does not fully co-segregate with the HDL condition and so may not be related.

The pedigree of family NL-120 is shown in Figure 3. Again the proband (II:01) has an HDL level below the fifth percentile (age and sex corrected). In both NL-003 and NL-120 multiple individuals with low HDL are observed. In family NL-003 individuals with low HDL and cardiovascular disease and cardiac events (MI) are observed.

Thus, the genes identified according to the invention are located on chromosome 9, at or near the 9q22 band. Markers for this locus have been identified and are as follows: 9q22ca7 (SEQ ID NO: 1) and 9q22ca17 (SEQ ID NO: 2). Other markers are available in the public domain.

5

Description of Gene95 and its mutations

Gene95 is alternately known and described herein as P1G95, gene95, 10 G95 or as HDL Regulatory Protein. Aspects of Gene95 are described at a variety of different sources in public databases.

Goldenpath Gene ID: ENSG00000136925, including transcript ID: ENST00000259452. (GoldenPath assembly of the Human Genome Project 15 Working Draft and found at www.genome.ucsc.edu or at the Ensembl web-site www.ensembl.org, version effective August 2001).

GenBank Accession Numbers: AK056453, XM_088573 (Available at www.ncbi.nlm.nih.gov/entrez/query.fcgi). Those skilled in the art will recognize 20 that these references do not provide the correct full length nucleotide coding sequences for gene95, nor do they provide the correct amino acid sequence of gene95 when translated.

The full length cDNA sequence for gene95 (P1G95) is set out in SEQ 25 ID NO: 3 comprising a 4333 bp transcript including 5'UTR and 3' tail. The exon/intron structure of gene95 is set out in Figure 4. The gene comprises 10 exons with possible alternate transcripts for exon 6 ("exon 6 alt" or E6a) and exon 9 ("exon 9 alt" or E9a). Figure 4 illustrates the expected 10 exon construct and other possible transcripts employing E6a or E9a.

30

The gene95 protein comprises a 516 amino acid protein (SEQ ID NO: 4). Use of an alternate methionine start site may generate a sequence of 489

amino acids. Analysis of the protein sequence of gene95 suggests it has the characteristics of a soluble protein which is involved in maintaining serum lipid homeostasis in humans. The protein is believed to contain one or more of the following features: N-glycosylation site (PS00001); Glycosaminoglycan attachment site (PS00002); 4 cAMP- and cGMP-dependent protein kinase phosphorylation sites (PS00004); 12 Protein kinase C phosphorylation sites (PS00005); 8 Casein kinase II phosphorylation sites (PS00006); 8 N-myristoylation sites (PS00008); Zinc finger C2H2 type domain (PS50157); Cysteine-rich region (PS50311).

10

For SEQ ID NO: 3, residues 1-400 represent the 5'-UTR (untranslated region) while the 3'UTR comprises residues 1952-end. For the mutant sequence of SEQ ID NO: 6, showing the T1802G mutation, the 5'-UTR region is shown as residues 1-400 and the 3'-UTR region as residues 1952-end. For the mutant sequence of SEQ ID NO: 8, showing the 1706C1707 mutation, the 5'-UTR region is shown as residues 1-400 and the 3'-UTR region as residues 1952-end.

15

Gene95 has a Rhodanese-like domain most closely related to group of hypothetical, uncharacterized bacterial proteins. An exemplary rhodanese-like domain is found at amino acids 304 - 406. There is no similarity of this gene to any other human gene, other than hypothetical or "rhodanese-like" or "sulfurtransferase-related" proteins. Rhodanese domains are found in a thiosulfate sulfurtransferase (e.g. Rhodanese; IPR001307). A public database search identified 21 hits in human genome with Rhodanese domains, 1 being a platelet adhesion molecule, the others being phosphatases. Other domain signatures such as a DnaJ central domain (e.g. [CXXCXGXG]4; amino acids 422-480), XS Zinc finger domain (e.g. amino acids 458-465) and integrase site (e.g. amino acids 452- 465) are also suggested.

20

25

30

Figure 5 sets out the nucleotide and amino acid sequences of individual exons, and some sequence from the promoter (genomic) and intron

regions (especially splice site junctions). The Gene95 sequence spans about 34kb of genomic DNA. Introns which are not fully set out may be obtained from the public human genome sequence database Goldenpath. Lower case letters indicate intron and promoter regions, while upper case letters indicate nucleotides in the cDNA or mRNA or amino acids, as dictated by the context. Exon 1 and Exon 2 have one or more asterisks ("**"). These are putative stop codons. The true initiator methionine is believed to be the first methionine in Exon 2 following the asterisk. Asterisks are also found in exon 10. The first asterisk is the expected termination site, generating a polypeptide of 516 amino acids. The remaining amino acid translations are illustrated for the sake of completeness and are not believed to lead to a functioning protein. Exon 6a and Exon 9a contain termination codons. If these alternate exons are used, they are believed to result in the truncated proteins, as indicated.

Homology: Among full length proteins, the closest homologs to human Gene95 are the shared 29 to 34 % identity of Rhodanese-related sulfurtransferases (*Salmonella typhimurium* and *Brucella melitensis*) and dihydrofolate reductase (*Schizosaccharomyces pombe*). Hypothetical bacterial proteins of highest homology include: Q9RVC9_DEIRA/119-216; Q55613_SYNY3/113-210; Q9Z7H1_CHLPN; 084632_CHLPN/113-212; 084632_CHLTR/113-212; 034131_LACLA/116-213; 031457_BACSU/116-213 (YBFQ protein).

This invention also discloses and claims mouse gene95 protein (SEQ ID NO: 5), the first non-human mammalian homolog of gene95. The sequence shares approximately 76% sequence identity across the full length of the protein with human gene95. Human and mouse amino acid sequences are aligned in Figure 6. Shared amino acids are indicated, along with conservative and non-conservative changes.

30

Additional investigations of short nucleic acid sequence segments from other mammals indicate that at the nucleotide level, mammalian species share a generally conserved gene95 sequence. Specifically:

- 5 Human:Cow 514/565 (90%) identical based on overlapping sequence
Human:Rat 338/401 (84%) identical based on overlapping sequence
Human:Pig 228/265 (86%), identical based on overlapping sequence
Human:Mouse 266/307 (86%) identical based on overlapping sequence

- 10 Expression pattern: Based on EST evidence, the gene is shown to be expressed in the following tissues and cell lines: teratocarcinoma, brain, placenta, ovarian tumor, lymphoma, melanoma, neuroblastoma. The data of Examples 2 and 3 confirm expression in a wide range of tissues.

- 15 Mutation 1, found in the family BC-11M, was identified as a 1802T>G (SEQ ID NO: 6) causing a Ser468Ala mutation SEQ ID NO: 7. The mutation was present in 13 affected family members and not present in 10 unaffected family members. The mutation was not found in 198 control chromosomes, nor in 164 chromosomes from individual with high HDL. Both control cohorts
20 were of similar ethnicity to the BC-11M family. The mutation may result in loss of a putative Protein Kinase A phosphorylation site (PKA- basic-basic-neutral-Ser). This mutation alters a serine residue that is conserved in the mouse protein.

- 25 Mutation 2, from an individual in the NL-003 family with HDL level <5th percentile comprises a 1706C1707 insertion SEQ ID NO: 8. The insert is in a second base of codon for Q436 resulting in Q436P and 39 additional unique amino acids producing a premature stop codon, 475aa total (SEQ ID NO: 9 and counting from the methionine at residue 14). Mutation 2 is also observed
30 in an individual from family NL-120 with HDL <5th percentile. Mutation 2 was not observed in 228 control chromosomes of similar ethnicity.

Alignments of the amino acid sequence of mutation 1 and mutation 2 with the wild-type amino acid sequence of human gene95 is set out in Figure 7.

5 Single Nucleotide Polymorphisms of the coding region (cSNPs) of *gene95* and other polymorphisms have been identified and are set out in Table 1. These cSNPs result in the amino acid changes identified, if any. Other cSNPs and polymorphisms in exonic or intronic regions of *gene95* can also be identified by those skilled in the art.

10

Because of the processing that may take place in transforming the initial RNA transcript into the final mRNA, the nucleotide sequences disclosed herein may represent less than the full genomic sequence. Such genes and cDNA sequences are still considered corresponding sequences because they
15 both encode similar RNA sequences. Thus, by way of non-limiting example only, a gene that encodes an RNA transcript, which is then processed into a shorter mRNA, is deemed to encode both such RNAs and therefore encodes an RNA complementary to (using the usual Watson-Crick complementarity rules), or that would otherwise be encoded by, a cDNA (for example, a
20 sequence as disclosed herein). Thus, the sequences disclosed herein correspond to genes contained in the cells and are used to determine relative levels of expression because they represent the same sequences or are complementary to RNAs encoded by these genes. Such genes also include different alleles and splice variants that may occur in the cells used in the
25 processes of the invention.

Thus, the polynucleotides, such as the gene sequences disclosed herein, for use in the screening assays of the invention "correspond to" *gene95* if the polynucleotide encodes an RNA (processed or unprocessed,
30 including naturally occurring splice variants and alleles) that is at least 50% identical, preferably at least 70%, 80%, 90% identical, and more preferably at least 95%, or 98% identical to, and especially having the sequence of, an

RNA that would be encoded by, or be complementary to, such as by hybridization with, a polynucleotide having SEQ ID NO: 3. In addition, genes including sequences at least 50% identical to SEQ ID NO: 3, preferably at least about 70%, 80%, 90% identical to such a sequence, more preferably at least about 98% identical to such sequence and most preferably comprising such sequences as are specifically contemplated by all of the processes of the present invention as being genes that correspond to these sequences. In addition, sequences encoding the same polypeptides and proteins as any of these sequences, regardless of the percent identity of such sequences, are also specifically contemplated by any of the methods of the present invention that rely on any or all of said sequences, regardless of how they are otherwise described or limited. Thus, any such sequences are available for use in carrying out any of the methods disclosed according to the invention. Such sequences also include any open reading frames, as defined herein, present within *gene95*. Such sequences include the mutant *gene95* sequences of SEQ ID NO: 6 and SEQ ID NO: 8, and sequences containing the alternative exons shown in Figure 5.

In accordance with the forgoing, the present invention encompasses an isolated polynucleotide comprising a polynucleotide sequence or the full complement of this polynucleotide sequence, wherein the polynucleotide sequence is at least 65%, preferably at least 75%, more preferably at least 85%, especially at least 90%, most preferably 95%, or even 98%, identical to SEQ ID NO: 3, with the sequence of SEQ ID NO: 3 especially preferred. The invention also includes an isolated polynucleotide comprising a polynucleotide sequence that encodes a polypeptide having the amino acid sequence set forth in SEQ ID NO: 4.

Relating to the *gene95* protein (SEQ ID NO: 4), the invention includes all those proteins, polypeptides and amino acid sequences corresponding to SEQ ID NO: 4. Such sequences corresponding to SEQ ID NO: 4 include any full length protein or fragment thereof which retains a biological activity of

gene95 protein. Such sequences are preferably at least about 50% identical to SEQ ID NO: 4, more preferably about 60%, 70%, 80% and most preferably at least about 90%, or 95%, identical to SEQ ID NO: 4. Such sequences include any ortholog or homolog of gene95 protein from any organism, preferably a eukaryote, more preferably a mammal, most preferably a rodent or human; and any amino acid sequence having at least about 50%, 60%, 70%, 80% and most preferably at least about 90% sequence identity thereto. Such sequences include mutant sequences SEQ ID NO: 7 and SEQ ID NO: 9, sequences corresponding to alternative open reading frames of *gene95* nucleotide sequences, and sequences found in the alternatively spliced exons in Figure 5.

In accordance with the foregoing, the present invention includes an isolated polypeptide comprising an amino acid sequence having at least 65%, preferably at least 75%, more preferably at least 85%, especially at least 90%, most preferably 95%, or even 98%, identity with the amino acid sequence set forth in SEQ ID NO: 4, wherein a polypeptide comprising the sequence of SEQ ID NO: 4 is especially preferred.

The present invention also relates to nucleic acid vector comprising such an isolated polynucleotide and a recombinant host cell comprising such a vector. The present invention also encompasses a method for producing the polypeptide of SEQ ID NO: 4 comprising culturing the host cell of claim 49 under conditions supporting production of the polypeptide, methods of which are all well known to those skilled in the art in light of the disclosure set forth herein.

Screening Assays using Gene95

30

The present invention provides screening assays using gene95 gene and/or protein for use in identifying therapeutic agents, especially agents

antagonistic to low HDL levels. One such protocol involves the screening of chemical agents for ability to modulate, either upward or downward, the activity of *gene95* so as to elevate HDL activity, such as by increasing HDL levels, especially plasma levels, in an animal, including humans. Agents that
5 alter the activity of the *gene95* gene, or active fragments or portions of it, or that may modulate the activity of polypeptides encoded by *gene95*, or polypeptides that act as transcription factors to modulate the activity of such genes, or other related gene segments, such as enhancers or other regulatory genetic elements that modulate the activity of *gene95*, acting either
10 in cis or trans fashion, are thereby identified and may prove useful in preventing, treating, or otherwise ameliorating, low HDL levels, or the effects of low HDL levels or diseases related to low HDL levels, such as by ameliorating reverse cholesterol transport or other lipid related processes, and/or for diseases such as cardiovascular disease, atherosclerosis, and
15 other diseases.

In accordance with the invention disclosed herein, there are provided compositions and methods for treating patients having low HDL-C, vascular disease, dyslipidemia, atherosclerosis or a related disorder, or for
20 ameliorating reverse cholesterol transport in the body, by administering compounds that modulate biological activity or expression of *gene95*.

The present invention specifically contemplates screening assays, such as where a large number of compounds are to be screened for activity in
25 modulating therapeutic target biological activity. As to all such assays as disclosed herein, such modulation may include either an increase or a decrease in therapeutic target biological activity.

Those skilled in the art are able to identify measurable biological
30 activities of a therapeutic target which can be usefully incorporated into low or high throughput screening assays. Non-limiting examples of such assays are described herein for illustration purposes. Based on these teachings, other

embodiments of therapeutic target screening assays will be directly reduced to practice.

5 The invention also provides assays for the identification of such therapeutic compounds and their analogs. Compounds that modulate the biological activity of *gene95* gene or protein are considered useful in the invention. Exemplary screening assays (*in vitro* or *in vivo*) and computational assays (*in silico*) for the identification of such compounds are detailed below. The screening assays of the invention simplify the evaluation, identification
10 and development of therapeutic agents for the treatment and prevention of low HDL and/or vascular diseases, dyslipidemias or related disorders. In general, the screening methods provide a facile means for selecting natural product extracts or synthetic compounds of interest from a large population (i.e. a chemical library) which are further evaluated and condensed to a few
15 active core structures. Multiple analogs of such core structures may be developed and tested to identify those preferred analogs which have improved characteristics as therapeutic agents.

The present invention also relates to a method for identifying an agent
20 that modulates the activity of a polypeptide whose activity alters high density lipoprotein (HDL)-activity, comprising:

- a) contacting a candidate compound with a polypeptide encoded by a polynucleotide corresponding to *gene95* under conditions facilitating such activity; and
 - 25 b) determining a change in the biological activity of said polypeptide as a result of said contacting;
- wherein said change in activity identifies the test compound as an agent that modulates said polypeptide biological activity.

30 In a one embodiment of this process, the change in biological activity in step (b) is a decrease or increase in activity of the polypeptide. In a preferred embodiment, the activity is measured by measuring the activity of an enzyme,

such as where the polypeptide itself has enzyme activity that can be directly or indirectly assayed. Such assays may be conducted *in vitro* or *in vivo*.

5 In a preferred embodiment, said polypeptide has the amino acid sequence of SEQ ID NO: 4; in an alternative embodiment, said polynucleotide has SEQ ID NO: 3.

10 In another embodiment, the polypeptide is present in a cell extract, a liposome or an intact cell. The present invention specifically contemplates embodiments in which the cell is a recombinant cell line containing a heterologous *gene95* construct. In other embodiments, said cell or extract is engineered by other than genetic engineering, such as where the activity of a polypeptide is to be enhanced and the cell has been engineered to contain, or have on its surface, said polypeptide but wherein the polypeptide is present
15 due to physical insertion of the polypeptide into the membrane or cytoplasm of the cell and not through expression of a gene contained in the cell.

The present invention also relates to a method for identifying an agent that modulates a Gene95 activity, comprising:

20 a) contacting a test compound with a polypeptide encoded by a polynucleotide corresponding to *gene95* under conditions supporting an activity of said polypeptide; and

b) determining a change in the activity of the polypeptide as a result of said contacting;

25 wherein said change in activity identifies the test compound as an agent that modulates a Gene95 activity.

Such determined change in activity in step (b) may be a decrease or an increase in activity. In one embodiment, the activity is measured by measuring
30 the activity of an enzyme. In other embodiments of such method, the polypeptide is present in a lipid bilayer, including where this lipid bilayer is part of a liposome. In addition, the polypeptide may be part of an intact cell, such

as where the intact cell is a cell that has been engineered to comprise said polypeptide, such as where the intact cell is a recombinant cell that has been genetically engineered to express said polypeptide, preferably where the cell does not express said polypeptide absent said engineering. In all cases, the
5 intact cell is preferably a mammalian cell.

The present invention also relates to a method for identifying an HDL-enhancing agent, comprising administering to an animal an effective amount of an agent found to have modulating activity using any of the assays
10 disclosed herein and detecting an increase in plasma HDL activity in said animal due to said administering thereby identifying an agent useful in enhancing HDL activity.

In a preferred embodiment, said animal exhibits low HDL activity prior
15 to administering said agent. In another preferred embodiment, the HDL-enhancing activity is an increase in HDL level in said animal, most preferably an increase in plasma HDL level and preferably where said animal is a human patient.

The present invention additionally relates to a method for treating a low-HDL related disorder in an animal afflicted with said disorder comprising administering to said animal an effective amount of an agent found to have HDL-enhancing activity using any of the assays of the invention. In a preferred embodiment, the animal to be treated is a human patient. In an
20 additional preferred embodiment, the disorder to be treated is selected from the group consisting of low HDL diseases, vascular diseases and dyslipidemias.
25

The agents identified according to the processes of the invention are
30 also useful for treating or preventing coronary artery disease, regardless of the HDL status of the patient. For example, a patient with normal HDL levels who has a family history of coronary artery disease would still be advised to

take a therapeutic agent according to the invention in order to elevate HDL levels and further reduce the risk of coronary artery disease. Thus, the patient does not need to have a dyslipidemia in order to be eligible for treatment according to the invention.

5

In general, the screening methods of the invention involve screening any number of compounds for therapeutically active agents by employing any number of *in vitro* or *in vivo* experimental systems. Exemplary methods useful for the identification of such compounds are detailed herein.

10

The methods of the invention simplify the evaluation, identification and development of active agents for the treatment and prevention of low HDL levels as well as cardiovascular disease (CVD) and dyslipidemias. In general, the screening methods provide a ready means for selecting natural product
15 extracts or compounds of interest from a large population which are further evaluated and condensed to a few active and selective materials. Positive candidates from this pool are then purified and evaluated in the methods of the invention to determine their HDL-raising, anti-CVD or anti-dyslipidemia activities or both. The positive candidates may be used directly as therapeutic
20 agents, or they may provide informative structures for structure-activity relationship (SAR) analysis and development of further analogs which then become the preferred therapeutic agents.

25 Assessment of Gene 95 as a sulfurtransferase responsible for HDL regulation.

While the human genetics data establishes that the function of Gene 95 is to maintain HDL levels in humans, the specific mechanism of action of
30 Gene 95 remains to be established. Without being bound to any theory for a mechanism of action, the inventors suggest that Gene 95 may function as a sulfurtransferase, or similar type enzyme. This is based on the comparison of

the Rhodanese domain found in the protein. Rhodanese domains may be classified as active for sulfurtransferase activity, active for phosphatase activity or catalytically inactive. Human and mouse G95 contain consensus for sulfurtransferase within the rhodanese domain. Possible consensus for phosphatase within rhodanese domain is found in the human but not conserved in mouse G95. In addition, one other human gene with this consensus has been annotated as a sulfurtransferase activity.

Several types of evidence connect these activities to HDL metabolism. For example, thioredoxin binding protein Txnip is known to be involved in lipid metabolism based on the hyperlipidemic mouse phenotype.

It is understood that screening assays employing a gene 95 sulfurtransferase biological activity may be designed using a known substrate for sulfurtransferases, such as cyanide, thioredoxin and dihydrolipoate. Alternatively, screening assays may be designed based on previously disclosed sulfurtransferase assays. In one colorimetric assay for thiocyanate production, the assay measures conversion of thiosulfate and cyanide to sulfite and thiocyanate. In an assay for NADPH oxidation by thioredoxin reductase, the assay measures conversion of thiosulfate and thioredoxin to sulfite and thioredoxinpersulfide. Compounds which agonize or antagonize these conversions via Gene 95 interaction are modulators of the invention.

Functional assays may be based on the activity of a polypeptide encoded by one or more of the polynucleotides disclosed herein as corresponding to *gene95*, including candidates with high homology thereto, such as polynucleotides at least 90% or 95% identical to such genes or polypeptides with high homology to the polypeptides encoded by said genes. Such assays may employ drug screening technology such as (but not limited to) the ability of various dyes to change color in response to changes in assay conditions resulting from the activity of the polypeptides.

Drug screening assays can also be based upon the ability of gene95 polypeptide to interact with other proteins. Such interacting proteins can be identified by a variety of methods known in the art, including, for example, radioimmunoprecipitation, co-immunoprecipitation, co-purification, and yeast
5 two-hybrid screening. The ability of test compounds to agonize or antagonize protein-protein interactions is a standard type of screening assay that may be employed. Such interactions can be assayed by means including but not limited to fluorescence polarization or scintillation proximity methods. Drug screens can be based upon a function or feature apparent upon creation of a
10 transgenic or knockout mouse, or upon overexpression of the protein or protein fragment in mammalian cells *in vitro*. Moreover, expression of mammalian (e.g., human) gene95 polypeptides in yeast or *C. elegans* allows for screening of candidate compounds in wild-type and mutant backgrounds, as well as screens for mutations that enhance or suppress a low HDL
15 phenotype. Modifier screens can also be performed in transgenic or knock-out mice.

It will be evident to those skilled in the art that the disclosure herein
20 facilitates incorporation of Gene95 into standard screening assays for identifying compounds that interact with and/or modulate gene95. Such assays include protein/compound binding assays, gene expression assays and many other types. Along with standard assays, known features of Gene95 suggest more specialized assays that may be employed. For
25 example, the putative phosphorylation sites suggest that an assay which measures a test compound's propensity to influence the rate, amount or timing of phosphorylation of gene95 would be a useful modulator of the invention, and a potential therapeutic agent or analog thereof for the diseases indicated herein. Features of gene95 which can be exploited for use in
30 screening include the N-glycosylation site, the Glycosaminoglycan attachment site; the 4 cAMP- and cGMP-dependent protein kinase phosphorylation sites; the 12 Protein kinase C phosphorylation sites; the 8 Casein kinase II

phosphorylation sites; the 8 N-myristoylation sites; the Zinc finger C2H2 type domain; and the Cysteine-rich region. Other features that may be useful for measurement, include the activity of the Rhodanese-like domain, the DnaJ central domain, the XS Zinc finger domain and the integrase site.

5

In accordance with the foregoing, the present invention relates to a method for identifying an agent that modulates the activity of a polynucleotide whose expression alters high density lipoprotein (HDL)-activity *in vivo*, comprising:

- 10 a) contacting a test compound with a polynucleotide corresponding to *gene95* under conditions facilitating expression of the polynucleotide; and
- b) determining a change in the expression of the polynucleotide as a result of said contacting;
- wherein said change in expression identifies the test compound as an
- 15 agent that modulates the activity of a polynucleotide whose expression alters high density lipoprotein (HDL)-activity.

 In specific embodiments of such a process, the change in expression in step (b) may be a decrease or increase in expression of said polynucleotide

20 or gene.

In another aspect, the present invention relates to a method for identifying an agent that modulates Gene95 activity, comprising:

- 25 a) contacting a test compound with a genetic construct comprising a reporter gene operably linked to a Gene95 promoter under conditions supporting transcription of said reporter gene;
- b) determining a change in transcription of the reporter gene as a result of said contacting
- wherein a change in said transcription indicates that the test compound
- 30 is an agent that modulates Gene95 activity.

Such determined changes may be an increase or decrease in the recited transcription and wherein transcription is determined by measuring the amount of an expression product encoded by said reporter gene, such expression product including either an RNA or a polypeptide. In preferred
5 embodiments, the reporter gene may be present in a liposome or in an intact cells, such as a mammalian cell. Preferred embodiments of such methods include use of a mammalian Gene95 promoter, such as a human promoter, preferably that shown in SEQ ID NO: 15, or a mouse promoter, preferably the promoter sequence in SEQ ID NO: 14. In all cases, the reporter gene is
10 commonly a gene whose expression is easily measured and will be other than Gene95 itself, although the latter is not excluded for use as a reporter gene.

Such a process is especially useful for identifying agents effective against low HDL levels and disorders, and symptoms thereof. Such agents or
15 their chemical analogs are also useful for modulating gene95 gene or protein and/or for treatment or prophylaxis of cardiovascular disease. An example of a construct comprising a human Gene95 promoter sequence is shown in SEQ ID NO: 15, wherein the promoter sequence (about the first 1500 bases) is at the start of the sequence and is followed by exon 1 (starting at residue 1502)
20 after which is intron 1 with exon 2 at the end of the sequence, while a sequence that incorporates a mouse promoter (about 1500 nucleotide residues) is shown in SEQ ID NO: 14, with the promoter at the beginning of the sequence, then followed by exon1 (starting at residue 1501), followed by intron 1 with exon 2 at the end of the sequence. The exonic sequences were
25 found in mRNA. The present invention encompasses such exon and promoter sequences.

In another aspect, the invention provides a method for computationally identifying a compound for modulating HDL levels and/or treating a vascular
30 disease or dyslipidemia. The method involves (a) determining the active site of the gene95 protein (i.e. through X-Ray crystallography or other techniques); and (b) through computational modeling, identifying a compound which

interacts with the active site, thereby identifying a compound, or its analog, as a compound which is useful for modulating HDL levels and/or treating a vascular disease, dyslipidemia or a related disorder.

5 The present invention further relates to a method for identifying a therapeutic agent, comprising:

 a) contacting a chemical agent with a polynucleotide corresponding to *gene95* under conditions supporting expression of said polynucleotide;

 b) determining a change in the expression of said polynucleotide as a
10 result of said contacting;

 wherein a change in said expression identifies a therapeutic agent.

 In a further embodiment, the present invention encompasses a method for identifying a therapeutic agent that modulates the activity of a polypeptide
15 that affects high density lipoprotein (HDL)-activity *in vivo*, comprising:

 a) contacting a test compound with a polypeptide encoded by a polynucleotide corresponding to *gene95* under conditions supporting an activity of said polypeptide; and

 b) determining a change in the activity of said polypeptide as a result
20 of said contacting;

 wherein a change in said activity identifies the test compound as a therapeutic agent that modulates the activity of a polypeptide that affects HDL activity.

25 In a preferred embodiment thereof, the polypeptide corresponds to SEQ ID NO: 4 and/or the polynucleotide corresponds to SEQ ID NO: 3

 Gene95 polypeptide, preferably of mammals, most preferably of rodent or human, can be used as an antigen to raise antibodies, including
30 monoclonal antibodies. Such antibodies will be useful for a wide variety of purposes, including but not limited to therapeutic uses for modulating gene95 biological activity, functional studies and the development of drug screening

assays and diagnostics. Monitoring the influence of agents (e.g., small organic compounds) on the expression or biological activity of gene95 polypeptide identified according to the invention can be applied not only in basic drug screening, but also in clinical trials. For example, the effectiveness of an agent determined by a screening assay as described herein to increase or decrease gene expression, protein levels, or biological activity can be monitored in clinical trials of subjects exhibiting low HDL levels due to inadequate gene expression, protein levels, or biological activity. Alternatively, the effectiveness of an agent determined by a screening assay to modulate expression of gene95, as well as structurally and functionally related genes, including genes with high homology thereto, and including protein levels, or biological activity can be monitored in clinical trials of subjects exhibiting decreased altered gene expression, protein levels, or biological activity. In such clinical trials, the expression or activity of the genes or polypeptides disclosed herein and, preferably, other genes that have been implicated in, for example, cardiovascular disease can be used to ascertain the effectiveness of a particular drug.

For example, and not by way of limitation, genes that are modulated in cells by treatment with an agent (e.g., compound, drug or small molecule) that modulates the activity of gene95, or any expression products thereof, or polypeptides that modulate that activity of any of such genes (e.g., identified in a screening assay as described herein) can be identified. Thus, to study the effect of agents on cholesterol levels or cardiovascular disease, for example, in a clinical trial, cells can be isolated and RNA prepared and analyzed for the levels of expression of gene95 and other genes implicated in similar or related disorders. The levels of gene expression can be quantified by Northern blot analysis or RT-PCR, or, alternatively, by measuring the amount of protein produced, by one of a number of methods known in the art, or by measuring the levels of biological activity of polypeptides encoded thereby or other genes. In this way, the gene expression can serve as a marker, indicative of the physiological response of the cells to the agent. Accordingly, this

response state may be determined before, and at various points during, treatment of the individual with the agent.

In a preferred embodiment, the present invention provides a method for
5 monitoring the effectiveness of treatment of a subject with an agent (e.g., an
agonist, antagonist, peptidomimetic, protein, peptide, anti-gene95 antibody,
antisense molecule, nucleic acid, small molecule, or other drug candidate
identified by the screening assays described herein) including the steps of (i)
obtaining a pre-administration sample from a subject prior to administration of
10 the agent; (ii) detecting the level of HDL activity or level of expression of
gene95 protein, mRNA, or genomic DNA in the pre-administration sample; (iii)
obtaining one or more post-administration samples from the subject; (iv)
detecting the level of expression or activity of gene95 protein, mRNA, or
genomic DNA or HDL in the post-administration samples; (v) comparing the
15 level of expression or activity of said protein, mRNA, or genomic DNA in the
pre-administration sample with that of the corresponding post administration
sample or samples; and (vi) altering the administration of the agent to the
subject accordingly. For example, increased administration of the agent may
be desirable to increase the expression or activity of *gene95* or its encoded
20 polypeptide, or to increase HDL-activity, such as plasma HDL-level, to higher
levels than detected, i.e., to increase the effectiveness of the agent.
Alternatively, decreased administration of the agent may be desirable to
decrease expression or activity of the polypeptide or gene where excess
expression contributes to lowering of HDL activity or levels.

25

The *gene95* genes disclosed herein as being involved in HDL
regulation, such as inducing low HDL levels in an animal, can be used, or a
fragment thereof can be used, as a tool to express a protein, where such
genes encode a protein, in an appropriate cell *in vitro* or *in vivo* (gene
30 therapy), or can be cloned into expression vectors which can be used to
produce large enough amounts of protein to use in *in vitro* assays for drug
screening. Expression systems which may be employed include baculovirus,

herpes virus, adenovirus, adeno-associated virus, bacterial systems, and eucaryotic systems such as CHO cells. Naked DNA and DNA-liposome complexes can also be used.

5 Assays of such activity include binding to intracellular interacting proteins, interaction with a protein that up-regulates gene or polypeptide activity, interaction with HDL particles or constituents, interaction with other proteins which facilitate interaction with HDL or its constituents, and measurement of cholesterol efflux. Furthermore, assays may be based upon
10 the molecular dynamics of macromolecules, metabolites and ions by means of fluorescent-protein biosensors. Alternatively, the effect of candidate modulators on expression or activity may be measured at the level of protein production using the same general approach in combination with standard immunological detection techniques, such as Western blotting or
15 immunoprecipitation with a specific antibody. Again, useful cholesterol-regulating or anti-CVD therapeutic modulators are identified as those which produce an change in activity that correlates with increased HDL levels, especially in the plasma of a test subject.

20 Candidate modulators (i.e., test compounds) may be purified (or substantially purified) molecules or may be one component of a mixture of compounds (e.g., a combinatorial library or an extract or supernatant obtained from cells). In a mixed compound assay, gene expression is tested against progressively smaller subsets of the candidate compound pool (e.g.,
25 produced by standard purification techniques, e.g., HPLC or FPLC; Ausubel et al.) until a single compound or minimal compound mixture is demonstrated to modulate gene or protein activity or expression in a manner having a beneficial effect on HDL levels.

30 Specific compounds which will modulate the gene expression or gene transcript levels in a cell of gene95 include antisense nucleic acids, ribozymes and other nucleic acid compositions and sequence specific binding

compounds which specifically hybridize with said gene (including exons or introns of such genes) or any RNA transcript of *gene95*. These specific compounds are compounds of the invention, and are useful for treating the diseases discussed previously. Design and manufacturing of such compounds are easily achieved by those skilled in the art based on the disclosures of the instant specification.

Specific compounds which modulate the activity of *gene95* polypeptide include antibodies (polyclonal or monoclonal) which specifically bind to an epitope of said polypeptide. These specific compounds are compounds of the invention, and are useful for treating the diseases discussed previously. Design and manufacturing of such compounds are well known to those skilled in the art.

Antibodies and antibody fragments that specifically recognize one or more epitopes of *gene95*, or epitopes of conserved variants of *gene95*, or peptide fragments of the *gene95* are also encompassed by the invention. Such antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (MAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab')₂ fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above. These may be used to treat any of the disorders disclosed herein.

As is known to those skilled in the art, use of fully humanized antibodies is generally preferred because they are generally less immunogenic and have a longer half-life when administered to humans. Leading available techniques include the UltiMab Human Antibody Development System(sm) featured by Medarex, Inc. (Princeton, NJ) which employs a transgenic mouse having a full suite of human genes for antibodies; and the Xenomouse technology of Abgenix, Inc. (Fremont, CA) which uses genetically engineered strains of mice in which mouse antibody

gene expression is suppressed and functionally replaced with human antibody gene expression, while leaving intact the rest of the mouse immune system.

These mice can be induced to generate fully humanized polyclonal
5 antibodies, which are then converted to large-scale production using
hybridoma technology. In one embodiment, the method includes immunizing a
transgenic non-human animal, *e.g.*, a transgenic mouse, having a genome
comprising a human heavy chain transgene and a human light chain
10 transgene, with a purified or enriched preparation of the gene95 protein, or a
fragment thereof. B cells (*e.g.*, splenic B cells) of the animal are then
obtained and fused with myeloma cells to form immortal, hybridoma cells that
secrete human monoclonal antibodies against the gene95 protein.

Humanized antibodies may also be produced, for example by replacing
15 an immunogenic portion of an antibody with a corresponding, but non-
immunogenic portion (*i.e.* chimeric antibodies) (Robinson, R. R. et al.,
International Patent Publication PCT/U.S.86/02269; Akira, K. et al., European
Patent Application 184,187; Taniguchi, M., European Patent Application
171,496; Morrison, S. L. et al., European Patent Application 173,494;
20 Neuberger, M. S. et al., PCT Application WO 86/01533; Cabilly, S. et al.,
European Patent Application 125,023; Better, M. et al., *Science* 240:1041-
1043 (1988); Liu, A. Y. et al. *Proc. Natl. Acad. Sci. USA* 84:3439-3443 (1987);
Liu, A. Y. et al., *J. Immunol.* 139:3521-3526 (1987); Sun, L. K. et al., *Proc.*
Natl. Acad. Sci. USA 84:214-218 (1987); Nishimura, Y. et al., *Canc. Res.*
25 47:999-1005 (1987); Wood, C. R. et al., *Nature* 314:446-449 (1985)); Shaw et
al., *J. Natl. Cancer Inst.* 80:1553-1559 (1988)). General reviews of
"humanized" chimeric antibodies are provided by Morrison, S. L. (*Science*,
229:1202-1207 (1985)) and by Oi, V. T. et al., *BioTechniques* 4:214 (1986).
Suitable "humanized" antibodies can alternatively be produced by CDR or
30 CEA substitution (Jones, P. T. et al., *Nature* 321:552-525 (1986); Verhoeyan
et al., *Science* 239:1534 (1988); Beidler, C. B. et al., *J. Immunol.* 141:4053-
4060 (1988)).

For the production of antibodies, various host animals may be immunized by injection with the gene95, a gene95 peptide (e.g., one corresponding to a functional domain of the protein), truncated gene95 polypeptides (gene95 in which one or more domains has been deleted), functional equivalents of the gene95 or mutants of the gene95. Such host animals may include but are not limited to rabbits, mice, goats and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanin, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and *Corynebacterium parvum*. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

There are various expression systems that can be used for the production of whole antibodies and antibody fragments. These include bacterial or mammalian cell culture and transgenic animals or plants. The expression system of choice is determined by the intended application and the desired yield, as is known by those skilled in the art. For example, animal cell culture and transgenic expression systems are desirable if glycosylation of the antibody is required, whereas bacterial expression systems are more efficient for production of unglycosylated antibodies, Fab fragments and the like. See Chad, HE and Chamow, SM. 2001. *Curr. Opin. Biotech.* 12: 188-193.

To generate fully human monoclonal antibodies to gene95, HuMab mice can be immunized with a preparation of gene95 or a fragment thereof, which has been purified or enriched according to any standard method. HuMab mice contain a human immunoglobulin gene miniloci that encodes

unrearranged human heavy (mu and gamma) and kappa light chain immunoglobulin sequences, together with targeted mutations that inactivate the endogenous mu and kappa chain loci (Lonberg, N. et al. (1994) Nature. 368(6474): 856-859.). These mice exhibit reduced expression of mouse IgM or kappa, and in response to immunization, the introduced human heavy and light chain transgenes undergo class switching and somatic mutation to generate high affinity human IgGkappa monoclonals.

Preferably mice are 6 – 16 weeks of age upon the first immunization. Initial immunization is intraperitoneal (IP) with antigen in complete Freund's adjuvant, followed by every other week IP immunizations (up to a total of 6) with antigen in incomplete Freund's adjuvant. The immune response can be monitored over the course of the immunization protocol with plasma samples obtained by retroorbital bleeds. The plasma can be screened, for example by ELISA or flow cytometry, and mice with sufficient titers of anti-gene95 human immunoglobulin can be used for fusions. Mice can be boosted intravenously with antigen 3 days before sacrifice and removal of the spleen. It is expected that 2-3 fusions for each antigen are needed for success.

For generation of hybridomas producing human monoclonal antibodies to gene95, the mouse splenocytes are first isolated and fused with PEG to a mouse myeloma cell line based upon standard protocols. The resulting hybridomas are then screened for the production of antigen-specific antibodies. For example, single cell suspensions of splenic lymphocytes from immunized mice are fused to one-sixth the number of P3X63-Ag8.653 nonsecreting mouse myeloma cells (ATCC, CRL 1580) with 50% PEG. Cells are plated at approximately 2×10^5 in flat bottom microtiter plate, followed by a two week incubation in selective medium containing 20% fetal calf serum, 18% "653" conditioned media, 5% origin (IGEN), 4 mM L-glutamine, 1 mM L-glutamine, 1 mM sodium pyruvate, 5 mM HEPES, 0.055 mM 2-mercaptoethanol, 50 units/ml penicillin, 50 mg/ml streptomycin, 50 mg/ml gentamycin and 1X HAT (Sigma; the HAT is added 24 hours after the fusion).

After two weeks, cells are cultured in medium in which the HAT is replaced with HT. Individual wells are then screened by ELISA for human anti-gene95 monoclonal IgM and IgG antibodies. Once extensive hybridoma growth occurs, medium is observed usually after 10-14 days. The antibody secreting hybridomas are replated, screened again, and if still positive for human IgG, anti-gene95 antibodies, can be subcloned at least twice by limiting dilution. The stable subclones are then cultured *in vitro* to generate small amounts of antibody in tissue culture medium for characterization.

10 To purify human anti-gene95 antibodies, selected hybridomas can be grown in two-litre spinner-flasks for monoclonal antibody purification. Supernatants can be filtered and concentrated before affinity chromatography with protein A-sepharose. (Pharmacia, Piscataway, NJ). Eluted IgG can be checked by gel electrophoresis and high performance liquid chromatography to ensure purity. The buffer solution can be exchanged into PBS, and the concentration can be determined by OD₂₈₀ using 1.43 extinction co-efficient. The monoclonal antibodies can be aliquoted and stored at -80°C until required for use according to the methods of the invention.

20 Another composition which can serve to increase HDL levels and/or treat the diseases discussed herein, is a nucleic acid construct comprising a *gene95* gene and combined into a gene-therapy delivery vehicle. Such vehicles may be simple aqueous buffers (for naked DNA delivery), viral based vehicles or non-viral (especially lipid-based) vehicles. These specific compounds are compounds of the invention, and are useful for treating the diseases discussed previously. Design and manufacturing of such compounds easily achieved by those skilled in the art based on the instant specification.

30 Agonists, antagonists, or mimetics found to be effective at modulating the level of cellular expression or activity may be confirmed as useful in animal models (for example, primates, mice, pigs, dogs, rabbits, or chickens).

For example, the compound may ameliorate the low HDL levels of mouse or chicken hypoalphalipoproteinemias.

5 A compound that promotes an increase in expression or activity of a gene or polypeptide that has the function of facilitating HDL production is considered particularly useful in the invention; such a molecule may be used, for example, as a therapeutic to increase the level or activity of HDL and thereby treat a low HDL condition in an animal (for example, a human).

10 The invention permits the identification of other HDL-related genes that may play a role in HDL-activity regulation and thus mutations in such genes may be important in studying other genes that are involved in HDL levels. Thus, for example, mutations that serve to stabilize gene95 proteins that otherwise contribute to elevating HDL levels have value. Such mutations
15 can be incorporated into any protein therapy or gene therapy undertaken for the treatment of low HDL-C levels. Similarly, compounds that increase the stability of a wild-type gene95 polypeptide or decrease its catabolism may also be useful for the treatment of low HDL-C or any other condition resulting from low HDL levels. Mutant forms of gene95 identified herein are also useful
20 for this purpose. Further mutations and compounds can be identified using the methods described herein.

In one such embodiment, cells expressing a gene95 polypeptide having a mutation are transiently metabolically labeled during translation and
25 the half-life of the said polypeptide is determined using standard techniques. Mutations that increase the half-life of the polypeptide are ones that increase protein stability. These mutations can then be assessed for HDL-related biological activity. They can also be used to identify proteins that affect the stability of corresponding mRNA or other proteins. One can then assay for
30 compounds that act on these factors or on the ability of these factors to bind such polypeptides.

In another example, cells expressing a wild-type *gene95* polypeptide are transiently metabolically labeled during translation, contacted with a candidate compound, and the half-life of the polypeptide is determined using standard techniques. Compounds that increase the half-life of the polypeptide
5 are useful compounds in the present invention.

In other embodiments, treatment with an agonist of the invention may be combined with any other HDL-raising or anti-CVD or anti-dyslipidemia therapies, or other conditions which require HDL management.

10

The assays of the invention comprise protein based assays. The polypeptide encoded by the *gene95* gene (purified or unpurified) can be used in an assay to determine its ability to bind another protein (including, but not limited to, proteins found to specifically interact with proteins known to be
15 involved in HDL-activity. Some examples would include ABCA1 protein and apolipoprotein. The effect of a compound on that binding is then determined.

In another type of binding assay for which the polypeptides encoded by genes disclosed herein are useful, the *gene95* polypeptide (or a polypeptide
20 fragment thereof or an epitope-tagged form or fragment thereof) is harvested from a suitable source (e.g., from a prokaryotic expression system, eukaryotic cells, a cell-free system, or by immunoprecipitation from expressing cells). The polypeptide is then bound to a suitable support (e.g., nitrocellulose or an antibody or a metal agarose column in the case of, for example, a his-tagged
25 form of said polypeptide). Binding to the support is preferably done under conditions that allow proteins associated with the polypeptide to remain associated with it. Such conditions may include use of buffers that minimize interference with protein-protein interactions. The binding step can be done in the presence and absence of compounds being tested for their ability to
30 interfere with interactions between said polypeptide and other molecules. If desired, other proteins (e.g., a cell lysate) are added, and allowed time to associate with the polypeptide. The immobilized polypeptide is then washed

to remove proteins or other cell constituents that may be non-specifically associated with it the polypeptide or the support. The immobilized polypeptide is then dissociated from its support, and proteins bound to it are released (for example, by heating), or, alternatively, associated proteins are released from the polypeptide without releasing the latter polypeptide from the support. The released proteins and other cell constituents can be analyzed, for example, by SDS-PAGE gel electrophoresis, Western blotting and detection with specific antibodies, phosphoamino acid analysis, protease digestion, protein sequencing, or isoelectric focusing. Normal and mutant forms of such polypeptide can be employed in these assays to gain additional information about which part of the polypeptide a given factor is binding to. In addition, when incompletely purified polypeptide is employed, comparison of the normal and mutant forms of the protein can be used to help distinguish true binding proteins.

15

In a specific example of such an assay, such assay is performed using a purified or semipurified protein or other molecule that is known to interact with a polypeptide encoded by a polynucleotide corresponding to gene95. This assay may include the following steps.

20

1. Harvest the gene95 polypeptide and couple a suitable fluorescent label to it;

25

2. Label an interacting protein (or other molecule) with a second, different fluorescent label. Use dyes that will produce different quenching patterns when they are in close proximity to each other vs. when they are physically separate (i.e., dyes that quench each other when they are close together but fluoresce when they are not in close proximity);

30

3. Expose the interacting molecule to the immobilized polypeptide in the presence or absence of a compound being tested for its ability to interfere with an interaction between the two; and
4. Collect fluorescent readout data.

Another assay is includes Fluorescent Resonance Energy Transfer (FRET) assay. This assay can be performed as follows.

1. Provide the gene95 protein or a suitable polypeptide fragment thereof and couple a suitable FRET donor (e.g., nitro-benzoxadiazole (NBD))
5 to it;
2. Label an interacting protein (or other molecule) with a FRET acceptor (e.g., rhodamine);
3. Expose the acceptor-labeled interacting molecule to the donor-labeled polypeptide in the presence or absence of a compound being tested
10 for its ability to interfere with an interaction between the two; and
4. Measure fluorescence resonance energy transfer.

Quenching and FRET assays are related. Either one can be applied in a given case, depending on which pair of fluorophores is used in the assay.
15

Gene95 may act by altering membrane permeability, such as the permeability of membranes to ions. Such activity may be assayed for using vesicles, such as liposomes or intact cells, wherein such structures comprise gene95 polypeptides of the invention, which polypeptides are expressed in
20 such vesicle, preferably an intact cell, such as a mammalian recombinant cell, and the permeability of the membrane of the cell is determined in the presence or absence of such expression. In the same way, such permeability can then be assayed in the presence and absence of chemical agents known to modulate the activity of gene95. Thus, the utility of these agents in
25 enhancing the activity of proteins known to affect such membrane transport can be readily determined. In the same way, the ability of these agents to affect the transport of other molecules, such as lipids, especially HDL, across such membranes is likewise readily determined.

30 In performing such assays, the test cell, such as the aforementioned mammalian recombinant cell expressing gene95, or a polynucleotide corresponding to such gene is loaded with a reporter molecule (such as a

fluorescent ion indicator whose fluorescent properties change when it binds a particular ion) that can detect ions, or alternatively, the external medium is loaded with such a molecule. A molecule which exhibits differential properties when it is inside the vesicle compared to when it is outside the vesicle may be used. For example, a molecule that has quenching properties when it is at high concentration but not when it is at another low concentration would be suitable. Alternatively, the effect of transport of ions (Ca, K, Na, metals and the like) across the membrane can be measured if the effect is to quench or unquench a dye which has been loaded into the medium or into the cell. The movement of the charged molecule (either its ability to move or the kinetics of its movement) in the presence or absence of a compound being tested for its ability to affect this process can be determined.

In still another assay, uptake of radioactive isotopes into or out of a vesicle can be measured. The vesicles are separated from the extravesicular medium and the radioactivity in the vesicles and in the medium is quantitated and compared.

As already disclosed above, the present invention also relates to assays that may employ transcription factors for one or more of the genes disclosed herein. The association between the polynucleotide to be tested and the binding factor may be assessed by means of any system that discriminates between protein-bound and non-protein-bound DNA (e.g., a gel retardation assay). The effect of a compound on the binding of a factor to such DNA is assessed by means of such an assay. In addition to binding assays, *in vitro* assays in which the regulatory regions of the gene are linked to reporter genes can also be performed. In a preferred embodiment, such polynucleotide is one that corresponds to *gene95*, most preferably wherein said polynucleotide has SEQ ID NO. 3.

30

The invention includes recombinant cell lines containing a *gene95* gene construct. Recombinant cell lines expressing the corresponding protein

are tested to identify a relevant biological activity of the protein that can be modulated by exposure to test compound(s). Compound(s) are systematically screened to evaluate whether they modulate the identified biological activity and those that effectively do so are then therapeutic agents, or analogs thereof, according to the invention.

Recombinant cell lines are also preferred for the preparation of purified protein, if a purified protein assay is desired. Those skilled in the art are capable of producing recombinant cell lines and extracting protein fractions containing highly purified proteins. These samples can be used in a variety of binding assays to identify compounds which interact with the proteins. Compounds that interact are therapeutic agents of the invention, or analogs thereof.

The invention also comprises the upstream untranslated regions and promoter regions of gene95. A segment of the promoter region is included in Figure 5. Larger portions of this promoter region can be now be identified by those skilled in the art, using this disclosure. The 5'UTR (untranslated region) is disclosed in SEQ ID NO. 3, 6, 8 and Figure 5. Such genomic or untranslated regions may be included in plasmids which are used in assays to identify compounds which modulate the expression of the identified gene. In one such assay, the upstream genomic region is ligated to a reporter gene, and incorporated into an expression plasmid. The plasmid is transfected into a cell, and the recombinant cell is exposed to test compound(s). Those compounds which increase or decrease the expression of the reporter gene are then modulators of the gene/protein, and are considered therapeutic agents of the invention.

The genes disclosed herein may also be involved in regulating cholesterol efflux. A transport-based assay for such activity can be performed *in vivo* or *in vitro*. For example, the assay may be based on any part of the reverse cholesterol transport process that is readily re-created in culture, such

as cholesterol or phospholipid efflux. Alternatively, the assay may be based on net cholesterol transport in a whole organism, as assessed by means of a labeled substance (such as cholesterol).

- 5 For high throughput screening, fluorescent lipids can be used to measure lipid efflux. For phospholipids, a fluorescent precursor, C6-NBD-phosphatidic acid, can be used. This lipid is taken up by cells and dephosphorylated by phosphatidic acid phosphohydrolase. The product, NBD-diglyceride, is then a precursor for synthesis of glycerophospholipids like
- 10 phosphatidylcholine. The efflux of NBD-phosphatidylcholine can be monitored by detecting fluorescence resonance energy transfer (FRET) of the NBD to a suitable acceptor in the cell culture medium. Suitable acceptors include rhodamine-labeled phosphatidylethanolamine, a phospholipid that is not readily taken up by cells. The use of short-chain precursors obviates the
- 15 requirement for the phospholipid transfer protein in the media. For cholesterol, NBD-cholesterol ester can be reconstituted into LDL. The LDL can efficiently deliver this lipid to cells via the LDL receptor pathway. The NBD-cholesterol esters are hydrolyzed in the lysosomes, resulting in NBD-cholesterol that can now be transported back to the plasma membrane and efflux from the cell.
- 20 The efflux can be monitored by the aforementioned FRET assay in which NBD transfers its fluorescence resonance energy to the rhodamine-phosphatidylethanolamine acceptor.

- Animal models are also useful in the assays of the invention.
- 25 Compounds identified as having activity in any of the above-described assays are subsequently screened in any available animal model system, including, but not limited to, pigs, rabbits, and chickens, to see if HDL levels are elevated as a result of such compounds being administered in an appropriately effective amount to said animal. Test compounds are
- 30 administered to these animals according to standard methods. Test compounds may also be tested in mice bearing mutations in interfere with cholesterol transport. Additionally, compounds may be screened for their

ability to enhance an interaction between a polypeptide encoded by a polynucleotide corresponding to *gene95* and any HDL particle constituent such as ApoA1, ApoAII, or ApoE.

5 Such cholesterol efflux assay measures the ability of cells to transfer cholesterol to an extracellular acceptor molecule and are usually dependent on the presence of a transporter molecule, such as ABCA1. Thus, the genes disclosed herein may play a role in modulating the activity of ABCA1, such as where a polypeptide encoded by a polynucleotide disclosed herein binds to, and modulates, the activity of ABCA1 or other HDL-related protein. In this
10 procedure, cells are loaded with radiolabeled cholesterol by any of several biochemical pathways (Marcil et al., *Arterioscler. Thromb. Vasc. Biol.* 19:159-169, 1999). Cholesterol efflux is then measured after incubation for various times (typically 0 to 24 hours) in the presence of HDL3 or purified ApoA1.
15 Cholesterol efflux is determined as the percentage of total cholesterol in the culture medium after various times of incubation. Compounds that modulate cholesterol efflux in this assay may be acting on the *gene95* protein target. Preferably, the cell is a recombinant cell line containing a *gene95* construct.

20 The invention also comprises a transgenic animal, such as a mouse, that has had one or both alleles of *gene95* inactivated (e.g., by homologous recombination) or conversely, a mouse having one or more additional copies of *gene95* or additional mutant copies of *gene95*. Such mice, including transgenic mice, represent a useful animal model for screening for
25 compounds that raise HDL-C levels. Such mice are also useful for experimental purposes to determine the role of *gene95* in living systems. Such an animal can be produced using standard techniques. In addition to the initial screening of test compounds, the animals having different versions of such genes are useful for further testing of efficacy and safety of drugs or
30 agents first identified using one of the other screening methods described herein. Cells taken from the animal and placed in culture can also be exposed

to test compounds. HDL-C levels can be measured using standard techniques, such as those described herein.

Compounds first identified as useful in elevating HDL activity using one
5 or more of the assays of the invention may be administered with a pharmaceutically-acceptable diluent, carrier, or excipient, in unit dosage form. Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer such compositions to patients. Although oral administration is preferred, any appropriate route of
10 administration may be employed, for example, parenteral, intravenous, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intracisternal, intraperitoneal, intranasal, aerosol, or oral administration. Therapeutic formulations may be in the form of liquid solutions or suspension; for oral administration, formulations
15 may be in the form of tablets or capsules; and for intranasal formulations, in the form of powders, nasal drops, or aerosols.

Typically, a successful gene95 modulating therapeutic agent will meet some or all of the following criteria. Oral availability should be at or above
20 20% (so that at least 20% is absorbed into the blood stream). Animal model efficacy should be less than about 2 mg/kg and the target human dose between 50 and 250 mg/70 kg, although doses outside of this range may be acceptable. The therapeutic index (or ratio of toxic dose to therapeutic dose) should be greater than 100. The potency (as expressed by IC₅₀ value) should
25 be less than about 10 μ M, preferably below 1 μ M, and most preferably below 100 nM. The agent should show reversible binding (i.e., competitive inhibition) and should be reasonably selective over unrelated targets, or related targets that cause unwanted side effects. The required dosage should be no more than about once or twice a day or at meal times.

30

Methods well known in the art for making formulations are found in, for example, Remington: The Science and Practice of Pharmacy, (19th ed.) ed.

A.R. Gennaro AR., 1995, Mack Publishing Company, Easton, PA. Formulations for parenteral administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may be used to control the release of the compounds. Other potentially useful parenteral delivery systems for agonists of the invention include ethylenevinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, or example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

In general, novel drugs for the treatment of aberrant cholesterol levels and/or CVD or dyslipidemia are identified from large libraries of both natural product or synthetic (or semi-synthetic) extracts or chemical libraries including combinatorial chemical libraries, according to methods known in the art. Those skilled in the field of drug discovery and development will understand that the precise source of test extracts or compounds is not critical to the screening procedure(s) of the invention. Accordingly, virtually any number of chemical extracts or compounds can be screened using the exemplary methods described herein. Examples of such extracts or compounds include, but are not limited to, plant-, fungal-, prokaryotic- or animal-based extracts, fermentation broths, and synthetic compounds, as well as modification of existing compounds. Numerous methods are also available for generating random or directed synthesis (e.g., semi-synthesis or total synthesis) of any number of chemical compounds, including, but not limited to, saccharide-, lipid-, peptide-, and nucleic acid-based compounds. Synthetic compound libraries are commercially available from Brandon Associates (Merrimack, NH) and Aldrich Chemical (Milwaukee, WI). Alternatively, libraries of natural compounds in the form of bacterial, fungal, plant, and animal extracts are

commercially available from a number of sources, including Biotics (Sussex, UK), Xenova (Slough, UK), Harbor Branch Oceanographics Institute (Ft. Pierce, FL), and PharmaMar, U.S.A. (Cambridge, MA). In addition, natural and synthetically produced libraries are produced, if desired, according to methods known in the art, e.g., by standard extraction and fractionation methods. Furthermore, if desired, any library or compound is readily modified using standard chemical, physical, or biochemical methods.

In addition, those skilled in the art of drug discovery and development readily understand that methods for dereplication (e.g., taxonomic dereplication, biological dereplication, and chemical dereplication, or any combination thereof) or the elimination of replicates or repeats of materials already known for their HDL-raising, anti-CVD and/or anti-dyslipidemia activities should be employed whenever possible.

15

When a crude extract is found to have cholesterol-modulating or anti-CVD activities, or both, further fractionation of the positive lead extract is necessary to isolate chemical constituent responsible for the observed effect. Thus, the goal of the extraction, fractionation, and purification process is the careful characterization and identification of a chemical entity within the crude extract having cholesterol-modulating or anti-CVD activities. The same *in vivo* and *in vitro* assays described herein for the detection of activities in mixtures of compounds can be used to purify the active component and to test derivatives thereof. Methods of fractionation and purification of such heterogeneous extracts are known in the art. If desired, compounds shown to be useful agents for the treatment of pathogenicity are chemically modified according to methods known in the art. Compounds identified as being of therapeutic value are subsequently analyzed using any standard animal model known in the art.

20
25
30

The invention further comprises the use of gene95 protein or protein fragments as therapeutic agents, and includes any modified forms of gene95

which retain the biological activity of gene95. These therapeutic agents can be administered to patients in need thereof, such as patients who would benefit by increasing gene95 biological activity either locally, regionally or throughout the body, as administered. Such patients include, but are not limited to, patients suffering from low HDL, dyslipidemia, cardiovascular disease and other disorders.

Functional gene95 protein, and soluble derivatives thereof, such as peptides corresponding to functional domains of *gene95* or modified versions of gene95 protein, can be produced by standard methods known in the art. Administration to patients can be intravenous, oral, intraperitoneal, or by any other method known in the art.

Diagnostics and Pharmacogenomics with gene95

Gene expression, both comparable and absolute, as well as biological activity, and mutational analysis can each serve as a diagnostic tool for low HDL; thus determination of the genetic subtyping of the gene sequence can be used to subtype low HDL individuals or families to determine whether the low HDL phenotype is related to a given protein function, as with the families used in accordance with the present invention. This diagnostic process can lead to the tailoring of drug treatments according to patient genotype, including prediction of side effects upon administration of HDL increasing drugs (referred to herein as pharmacogenomics). Pharmacogenomics allows for the selection of agents (e.g., drugs) for therapeutic or prophylactic treatment of an individual based on the genotype of the individual (e.g., the genotype of the individual is examined to determine the ability of the individual to respond to a particular agent).

The present invention further relates to processes diagnosing the presence of a disorder, especially at its earliest stages, or the risk to a patient of developing such disorders. Thus, in another aspect, the present invention

relates to a process for diagnosing the presence of a disorder in a patient suspected of being afflicted therewith comprising detecting a mutation in the *gene95* gene in the genome of said patient. In a preferred embodiment, the present invention relates to such diagnostic processes where the mutation is
5 the mutation in the nucleotide sequence as depicted in SEQ ID NO: 6 and/or SEQ ID NO: 8 and/or Table 1.

In particular embodiments of such a process, the mutation is detected in a sample of DNA taken from said patient. Such a sample may be obtained in any manner commonly used to obtain such sample, such as by blood
10 sample, biopsy or other methods. Further in accordance with the processes of the invention, such detecting may be accomplished *in vivo*, such as where an *in situ* procedure is used to detect the presence of a mutated *gene95* gene or nucleotide sequence in a patient. The disorders that can be so detected are not limited to low HDL, dyslipidemia, cardiovascular disease, and the other
15 disorders thereby included, disclosed previously

In accordance with the foregoing, the present invention relates to a process for diagnosing the presence of an *gene95*-linked disease in a patient suspected of being afflicted therewith comprising detecting a mutation in the *gene95* gene in the genome or mRNA of said patient.

20 In preferred embodiments, the invention relates to such a process wherein said mutation is detected in a sample of DNA taken from the patient, most preferably wherein the mutation is the mutation of SEQ ID NO. 6 or SEQ ID NO. 8 or Table 1.

Many different techniques are known for detecting the presence or
25 absence of such a mutation. In preferred embodiments, said detecting is accomplished by determining the ability of a nucleic acid probe comprising at least 15 contiguous nucleotides that are complementary to a mutated portion of the sequence of SEQ ID NO: 1, most preferably wherein said probe comprises at least 30 contiguous nucleotides, especially where the probe
30 comprises at least 50 contiguous nucleotides.

The processes disclosed herein are also useful in determining the risk of a patient in developing one or more of the above disorders, so that the present invention also relates to a process for determining a patient's risk of developing a disorder where said patient is suspected to be at risk thereof, comprising detecting a mutation in the *gene95* gene in the genome or mRNA of said patient. Such detection may, in keeping with the foregoing, be by either *in vitro* or *in vivo* means. In a preferred embodiment, said disorder is low HDL, dyslipidemia and/or cardiovascular disease. In a preferred embodiment, the mutation is a mutation in the gene corresponding to SEQ ID NO: 1.

It is equally an embodiment of the invention to diagnose a disorder using detection of the *gene95* protein in a tissue or body sample, especially the detection of mutant *gene95* protein or the level of mutant or normal *gene95* protein. Such detection may be achieved by a variety of methods, but typically involves use of an anti-*gene95* antibody in a standard ELISA assay. On the basis of this disclosure, those skilled in the art may now develop diagnostic tools for detecting mutant or normal *gene95* in patient samples, for the diagnosis of various disorders.

Agents, or modulators, having a stimulatory or inhibitory effect on the *gene95* gene, or gene product, can be administered to individuals to treat disorders associated with low HDL-activity or level. In conjunction with such treatment, the pharmacogenomics (i.e., the study of the relationship between an individual's genotype and that individual's response to a foreign compound or drug) of the individual may be considered. Differences in efficacy of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug. Thus, the pharmacogenomics of the individual permits the selection of effective agents (e.g., drugs) for prophylactic or therapeutic treatments based on a consideration of the individual's genotype. Such pharmacogenomics can further be used to determine appropriate dosages

and therapeutic regimens. Accordingly, the genetic complement of an individual with respect to the genes disclosed herein can be determined to thereby select appropriate agent(s) for therapeutic or prophylactic treatment of the individual.

5

Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons (Eichelbaum, M., Clin. Exp. Pharmacol. Physiol., 23:983-985, 1996; Linder, M. W., Clin. Chem., 43:254-266, 1997). In general, two
10 types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). Altered drug action may occur in a patient having a polymorphism (e.g., an single nucleotide
15 polymorphism or SNP) in promoter, intronic, or exonic sequences of *gene95*. Thus by determining the presence and prevalence of polymorphisms allow for prediction of a patient's response to a particular therapeutic agent. In particular, polymorphisms in the promoter region may be critical in determining the risk of HDL deficiency and CVD. In addition to mutations,
20 polymorphisms of *gene95* may likewise be relevant to the identification and use of agents identified using the assays disclosed herein.

In addition, different agents may have different abilities to affect the genes of a signature gene set. For example, if a potential therapeutic agent,
25 say, agent A, causes a gene, or group of genes, related to low HDL levels to exhibit decreased expression, such as where a lower amount of mRNA is expressed from said gene(s), or less protein is produced from said mRNA, but a second potential agent, say, agent B, while modulating the activity of the same or related genes causes said expression to be reduced to half, such as
30 where only half as much mRNA is transcribed or only half as much protein is translated from said mRNA as for agent A, then agent B is considered to have twice as much therapeutic potential as agent A.

The present invention also relates to a process that comprises a method for producing a product, including the generation of test data, comprising identifying an agent according to one of the disclosed processes for identifying such an agent (i.e., the therapeutic agents identified according to the assay procedures disclosed herein) wherein said product is the data collected with respect to said agent as a result of said identification process, or assay, and wherein said data is sufficient to convey the chemical character and/or structure and/or properties of said agent. For example, the present invention specifically contemplates a situation whereby a user of an assay of the invention may use the assay to screen for compounds having a desired polypeptide, for example, enzyme, modulating activity, or gene expression modulating activity, and, having identified the compound, then conveys that information (i.e., information as to structure, dosage, etc) to another user who then utilizes the information to reproduce the agent and administer it for therapeutic or research purposes according to the invention. For example, the user of the assay (user 1) may screen a number of test compounds without knowing the structure or identity of the compounds (such as where a number of code numbers are used the first user is simply given samples labeled with said code numbers) and, after performing the screening process, using one or more assay processes of the present invention, then imparts to a second user (user 2), verbally or in writing or some equivalent fashion, sufficient information to identify the compounds having a particular modulating activity (for example, the code number with the corresponding results). This transmission of information from user 1 to user 2 is specifically contemplated by the present invention.

In accordance with the foregoing, the present invention relates to a method for producing test data with respect to the modulating activity of a test compound comprising:

(a) contacting a test compound with a Gene95 polynucleotide or Gene95 polypeptide, or a polynucleotide construct comprising a reporter gene

operably linked to a Gene95 promoter, under conditions wherein said polynucleotide or reporter gene is being transcribed or said polypeptide is active,

(b) determining a change in the activity of said polypeptide or transcription of said polynucleotide or reporter gene as a result of said contacting, and

(c) producing test data with respect to the modulating activity of said test compound based on a change in the transcription of the determined polynucleotide or reporter gene or activity of the determined polypeptide wherein said change shows modulating activity.

Example 1

Mutations in Gene95 cause low HDL in humans

15

METHODS

Patient Ascertainment and Sample Collection

Kindred BC11M, of Dutch origin was identified as part of a collaboration between the Department of Medical Genetics at the University of British Columbia and St Paul's Hospital in Vancouver, British Columbia. This kindred was ascertained based on a hypoalphalipoproteinemia phenotype (<5th percentile) in the absence of other lipid and clinical abnormalities (e.g. obesity and diabetes). A history of coronary artery disease was evident in this kindred at the time of ascertainment. Additional Dutch kindreds NL-003, NL-120, were ascertained as part of the patient referral program to the lipid clinic at the Academic Medical Center in Amsterdam based on abnormal cholesterol levels. A control cohort of normolipidemic individuals (HDL >20th percentile and <80th percentile) was used to validate the causal nature of the mutation.

30 Markers and Genotyping

Information regarding genetic markers was obtained from the Genome Database and GenBank. All markers used for genome scan and fine mapping had been previously localized on the Marshfield map. An 'x' was appended to many of the marker names for internal use. Genomic DNA was genotyped
5 using an Applied Biosystems Prism 3100 Genetic Analyzer running GeneMapper software (Applied Biosystems). Mendelian inheritance of alleles was verified using the PedCheck program.

Linkage Analyses

10 Two-point linkage analysis was performed using the MLINK program v4.1p from the FASTLINK software package and multipoint linkage analysis was performed using VITESSE v.1.0. An autosomal dominant inheritance model was used, assuming that 10% of all low HDL (<5th percentile) in the population is due to a mutation in the gene. The disease allele frequency was assumed
15 to be 0.25%, with 98% penetrance and a phenocopy rate of 4.5% in non-carriers. Marker allele frequencies were estimated from a large collection of American and European samples. Haplotypes were manually reconstructed and cross-validated using SIMWALKv2.8.

20 RESULTS

Linkage analysis of family BC11M:

Twenty-four individuals from family BC11M were included in a 400 marker genome scan of 12 multiplex pedigrees segregating isolated hypoalphalipoproteinemia in a dominant fashion. Power analysis suggested
25 that the BC11M kindred was suitable to identify an HDL locus using a linkage based approach under an autosomal dominant model (MaxE (Zmax 5cM) = 4.762). Two point linkage analysis of genome scan data gave a suggestive LOD score on chromosome 9 (D9S1677 LOD =2.285). This LOD score was followed up by multipoint linkage analysis, saturation genotyping and
30 haplotyping with additional markers on an expanded pedigree. The region on

Table 2. Candidate gene position definitions based on affected and unaffected individuals in the BC11M pedigree. Two candidate gene intervals are possible when using unaffected individuals.

MARKER	cM	cM map	BC11M Affecteds		BC11M Unaffected									
			308	311	4141	4077	4055	4057						
D9S273	0.662	0												
D9S166x	0.177	0.662												
D9S1799x	1.91	0.839												
D9S1876x	2.923	2.749												
D9S175	1.215	5.672												
D9S1834	0.908	6.887												
D9S1674	1.937	7.795												
D9S1780x	0.705	9.732												
D9S1843	3.2	10.437												
D9S264x	0.402	13.637												
D9S167	0.402	14.039												
D9S152x	0.301	14.441												
D9S1877x	1.523	14.742												
D9S1790x	0.2	16.265												
D9S1120x	0.1	16.465												
D9S1865x	0.301	16.565												
D9S249x	0.503	16.866												
D9S252x	0.301	17.369												

Table 2 -- Continued

D9S1812	1.42	17.67
D9S253x	0	19.09
D9S278x	1.01	19.09
D9S777x	0.807	20.1
D9S283	0.402	20.907
D9S1820x	3.844	21.309
D9S1803x	0.2	25.153
D9S197x	0.1	25.353
D9S196x	0.301	25.453
D9S1689x	0.604	25.754
9q22x-ca7	0.1	26.358
9q22x-ca6	0.1	26.458
9q22x-ca21	1.112	26.558
D9S287	2.776	27.67
9q22x-cal6	0.2	30.446
9q22x-cal7	5.379	30.646
D9S1690		
D9S271	1.937	36.025
D9S306x	0.503	37.962
D9S1784x	4.278	38.465
D9S1677	5.268	42.743
D9S289	0	48.011

chromosome 9 was supported by multipoint linkage analysis, and the multipoint LOD rose to 8.0, defining an affecteds only interval of 20.91 cM (Interval 1; D9S1780 to 9q22xca17) (Table 2). This interval could be further into sub-regions based on chromosomal breakpoints in unaffected individuals (Interval 2; 9q22xca7 to 9q22x-ca17) (Interval 3; D9S1812 to D9S1803x) (Table 2). Interval 2 was the focus for the most comprehensive mutation detection effort.

Example 2

10 Tissue distribution of Gene 95 using an Origene cDNA panel.

Twenty-four serially diluted (4-log range to ensure linear amplification) cDNA clones arrayed into a multi-well PCR plate were obtained from Origene (Rockville, MD). PCR was performed using gene-specific primers for Gene 15 95 (sometimes "G95" herein). Reactions were in 10 µl and contained 1.0 µl 10x buffer (Roche Molecular Biochemicals, Indianapolis, IN, USA), 0.25 mM of each dNTP (Boehringer Mannheim), 5 pmole of forward primer and reverse primer, and 0.25 unit of Taq DNA polymerase (Roche Molecular Biochemicals, Indianapolis, IN, USA).

20

Forward primer: CTGTGTCAGCACCTGCACCTC SEQ ID NO. 10
Reverse primer: ATCCCCATGGGCACGATTTC SEQ ID NO. 11

The amplified fragment lies between exons 4 and 6, and has a product size of 25 230 bp.

DNA Engine Tetrad cyclers (MJ Research, Inc., Waltham, MA, USA) were used for PCR amplification. The conditions for PCR were a 3-min denaturation step at 94°C, followed by 35 cycles at 94°C for 30 sec, 50°C for 30 30 sec, and 72°C for 1 min. A final extension step of 7 min at 72°C was performed and samples were maintained at 10°C. PCR products were

analyzed by electrophoresis on 2% agarose gels in 1x TBE. A 100 bp ladder (Gibco-BRL, Rockville, MD, USA) was used as size standard.

Table 3

Human Tissue (Origene)	G95 Tissue Expression Levels
Tissue	by PCR
Muscle	H
Heart	H
Placenta	H
Plasma Blood Leucocytes	H
Brain	M
Lung	M
Kidney	L
Liver	L
Spleen	L
Small Intestine	L
Adrenal Gland	H
Fetal Brain	H
Fetal Liver	H
Ovary	H
Prostate	H
Stomach	H
Testis	H
Thyroid	H
Pancreas	M
Salivary	M
Uterus	M
Bone Marrow	L
Skin	L
Colon	no expression

5

Relative levels of G95 cDNAs are set forth in Table XX. H=high, M=medium, L=low.

10

Example 3

Tissue Expression by Northern Blot

Quantitation and sizing of the Gene 95 transcript were analyzed by use
5 of a human 12-Lane multiple tissue Northern blot (BD Biosciences Clontech,
Palo Alto, CA, USA). The human blot was hybridized with a 401 bp probe for
Gene 95 from exons 6 to 9. A 4.4 kb band was identified, as expected. Actin
was used as the control.

Forward primer 5' TTTCCAGAATTGCGTGTTGGTG 3' SEQ ID NO. 12
10 Reverse primer 5' TGGATGCCACCCTTGAGCTG 3' SEQ ID NO. 13

Results (Figure 9) show that Gene 95 is ubiquitously expressed with
highest levels in muscle and heart. These results were confirmed by Northern
blot analysis of mouse tissues (data not shown). In one such run, using
15 fibroblasts, approximately 24 hours prior to cholesterol treatment, 2×10^5 cells
were plated into each well in a 6-well format so as to obtain 50-70%
confluency the following day. Cells were treated with a final concentration of
30 $\mu\text{g/ml}$ cholesterol for 24 h followed by total RNA preparation. The control
was Gene 95 expression from unaffected cell lines.

20

Example 4

Gene 95 expression in patient fibroblasts

25

The Ser to Ala mutation within exon 10 of Gene 95 is present in four
patient fibroblasts (400, 558, 549, and 575). We decided to compare the
expression of Gene 95 in these fibroblasts to normal controls (226, 475, and
485). This analysis was performed in the absence and presence of
30 exogenous cholesterol, in order to explore a connection between lipid
metabolism and Gene 95. Quantitative Real Time PCR (or "TaqMan") assays

were performed as follows. Human Gene 95 primers and their probes were designed using Primer Express software (Applied Biosystems, Foster City, CA).

- 5 Forward primer: 5' CCAAGGGAGTGTGCAAGG -3' SEQ ID NO. 31
Reverse primer: 5' CCTTTGTAAAAGCCATCAGGAACT-3' SEQ ID NO. 32

RT-PCR was carried out in an ABI 7900 sequence detection system
10 in a final volume of 25 μ l, containing 120 ng of total RNA for human Gene 95 or 50 ng for human apoA1, 200 μ M primers, and 600 μ M probe in 1x Taqman one-step RT-PCR Master mix (Applied Biosystem, CA). GAPDH or 18s (human) (Applied Biosystems) was used as the internal control. Data quantification and analysis was performed according to manufacturer's
15 protocol. Briefly, ΔC_T for the calibrator and samples was obtained by subtracting the VIC C_T value of 18s RNA or GAPDH from the FAM C_T value of the gene of interest. $\Delta\Delta C_T$ was calculated by subtracting the average ΔC_T (calibrator) values from ΔC_T (sample). The mRNA quantity for the calibrator is expressed as 1 x sample and all other quantities are expressed as a number
20 of percentage changes relative to the calibrator. Each sample was assayed in triplicate and standard error (SE) was calculated. RT-PCR reactions without RNA, and reactions with RNA but without reverse transcriptase were used as negative controls. The size of the PCR product was confirmed by agarose gel.

25 Overall, extremely low levels of expression of Gene 95 were found in all fibroblasts, including controls. TaqMan results indicated that Gene 95 expression in two patient cell lines (400 and 575) was down regulated by approximately 50% compared to the controls either with or without cholesterol treatment. Expression of Gene 95 in patient 558 did not vary significantly from
30 the controls. However, the expression of Gene 95 in 549 was elevated above controls (data not shown).

A trend towards reduced Gene 95 expression in mutation carriers was noted. Messenger RNA expression levels may be sensitive to cell culture conditions, cell density and passage number. Without desiring to be bound to any theory of mechanism of action, it is suggested that this trend towards

5 decreased levels of Gene 95 mRNA in mutation carriers may be the underlying mechanism of the low HDL condition in these patients.